Faeth Therapeutics, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
25.8M
on 2026-06-30, from 1.25M on 2024-03-31 10-Q ↗
Earlier counts are adjusted for the 1-for-20 reverse split; each bar's tip shows the count as filed.
Newest
No limit
S-3ASR of 2026-06-18. An automatic shelf: the form sets no dollar limit. Sales under the at-the-market programme filed with it are not stated apart. S-3ASR ↗
$150.0M
TD Securities (USA), agreement of 2026-06-18. No at-the-market sales statement read from a 10-Q or 10-K. S-3ASR ↗
Warrants
The 10-Q filed 2026-08-04 is not read yet.
Cash
22 quarters
$186.4M on 2026-06-30 ÷ $8.5M a quarter of operating cash used, the average of four quarters. 10-Q ↗
Raised: 1 of its filings are not read yet.
Also on file: a 1-for-20 reverse split, 2025-06-12 8-K ↗